Neurocrine Biosciences (NBIX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Catalyst-Rich 6 Months Ahead for Neurocrine Bio. (NBIX), Cowen Notes
July 30, 2015 9:53 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $55.00 (from $45.00), saying the company is gearing up for a catalyst-rich 6 months.
Nadeau commented, "NBIX's pipeline should yield a number of catalysts over the next 6... More
